- Home
- NBBK vs DCTH Comparison
NBBK vs DCTH Comparison
Compare NBBK & DCTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NBBK
- DCTH
- Stock Information
- Founded
- NBBK 1892
- DCTH 1988
- Country
- NBBK United States
- DCTH United States
- Employees
- NBBK N/A
- DCTH N/A
- Industry
- NBBK
- DCTH Medical/Dental Instruments
- Sector
- NBBK
- DCTH Health Care
- Exchange
- NBBK Nasdaq
- DCTH Nasdaq
- Market Cap
- NBBK 661.3M
- DCTH 630.4M
- IPO Year
- NBBK N/A
- DCTH N/A
- Fundamental
- Price
- NBBK $16.22
- DCTH $15.34
- Analyst Decision
- NBBK Buy
- DCTH Strong Buy
- Analyst Count
- NBBK 1
- DCTH 4
- Target Price
- NBBK $22.00
- DCTH $24.00
- AVG Volume (30 Days)
- NBBK 295.7K
- DCTH 508.1K
- Earning Date
- NBBK 07-23-2025
- DCTH 08-04-2025
- Dividend Yield
- NBBK N/A
- DCTH N/A
- EPS Growth
- NBBK 421.39
- DCTH N/A
- EPS
- NBBK 1.18
- DCTH N/A
- Revenue
- NBBK $169,131,000.00
- DCTH $53,850,000.00
- Revenue This Year
- NBBK N/A
- DCTH $147.90
- Revenue Next Year
- NBBK N/A
- DCTH $43.51
- P/E Ratio
- NBBK $13.79
- DCTH N/A
- Revenue Growth
- NBBK 27.71
- DCTH 1068.87
- 52 Week Low
- NBBK $14.20
- DCTH $7.12
- 52 Week High
- NBBK $21.05
- DCTH $18.23
- Technical
- Relative Strength Index (RSI)
- NBBK 39.05
- DCTH 47.93
- Support Level
- NBBK $15.44
- DCTH $15.72
- Resistance Level
- NBBK $17.05
- DCTH $17.35
- Average True Range (ATR)
- NBBK 0.39
- DCTH 0.81
- MACD
- NBBK -0.03
- DCTH -0.27
- Stochastic Oscillator
- NBBK 45.09
- DCTH 9.86
About NBBK NB Bancorp Inc.
NB Bancorp Inc operates as the holding company of Needham Bank. Its business consists of taking deposits from the general public and investing those deposits, together with funds generated from operations, in commercial real estate and multifamily loans, one- to four-family residential real estate loans, construction and land development loans, commercial and industrial loans, and consumer loans.
About DCTH Delcath Systems Inc.
Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.